

# PRESS STATEMENT



**For immediate release**

## **MSD RESPONSE TO THE PUBLICATION OF THE ACCELERATED ACCESS REVIEW**

**Hoddesdon, 24 October 2016**

Today, the Government published the Accelerated Access Review. First published in 2015, the aim of the AAR is to make the UK the fastest place in the world for the design, development and widespread adoption of medical innovations.

Louise Houson, MD for UK & Ireland, MSD welcomed the publication of the final report saying: “MSD welcomes the final publication of the Accelerated Access Review and supports its vision to deliver both improved health for patients and value for the NHS through better access and uptake of innovation.

“The AAR presents a well thought out blueprint for health and life sciences, not only placing innovation at the heart of the NHS to deliver truly outstanding healthcare, but identifying the building blocks and structures needed to help embed it across the NHS from bench to the patient, end to end. We are pleased to have been able to play a central role in the shaping of policy initiatives such as EAMS, which has contributed to the development of the proposed Accelerated Access Pathway announced today.

“We welcome the clear commitment from all parties involved to collaborate and engage earlier with industry through the Accelerated Access Partnership which we hope will lead the way for a reformed NICE process and speedier access and uptake of innovation will all help us to deliver the best care possible for patients.

“Of course, there is much detail to work through to ensure sensible and practical implementation.

“We look forward to continued partnership working with the Government, regulators and NHSE to realise the potential that the Report sets out for improving and speeding access to transformative therapies.”

–ends–

### **About MSD**

For 125 years, MSD has been a global healthcare leader working to help the world be well. MSD is a trade name of Merck & Co., Inc., Kenilworth, NJ., USA. Through

our prescription medicines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programmes and partnerships. For more information, visit [www.msd-uk.com](http://www.msd-uk.com).

**For further information please contact:**

Name: Meral Nugent

Tel: 01992 467272

Mob: 07884 232042

[Meral.nugent@merck.com](mailto:Meral.nugent@merck.com)